Global Strategic Investment Solutions LLC Purchases New Holdings in Orthofix Medical Inc. $OFIX

Global Strategic Investment Solutions LLC acquired a new position in Orthofix Medical Inc. (NASDAQ:OFIX) during the 2nd quarter, HoldingsChannel reports. The fund acquired 57,875 shares of the medical device company’s stock, valued at approximately $529,000.

Several other large investors also recently bought and sold shares of OFIX. R Squared Ltd raised its holdings in shares of Orthofix Medical by 7.2% during the first quarter. R Squared Ltd now owns 13,518 shares of the medical device company’s stock valued at $155,000 after acquiring an additional 904 shares during the last quarter. Gabelli Funds LLC boosted its stake in shares of Orthofix Medical by 0.4% in the fourth quarter. Gabelli Funds LLC now owns 235,303 shares of the medical device company’s stock worth $3,567,000 after acquiring an additional 1,000 shares during the last quarter. Raymond James Financial Inc. increased its position in shares of Orthofix Medical by 1.5% during the third quarter. Raymond James Financial Inc. now owns 66,812 shares of the medical device company’s stock worth $978,000 after purchasing an additional 1,000 shares in the last quarter. Amundi increased its position in shares of Orthofix Medical by 2.7% during the fourth quarter. Amundi now owns 41,527 shares of the medical device company’s stock worth $630,000 after purchasing an additional 1,086 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Orthofix Medical by 6.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,561 shares of the medical device company’s stock valued at $335,000 after purchasing an additional 1,213 shares during the last quarter. 89.76% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have issued reports on OFIX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Orthofix Medical in a research note on Friday, July 17th. TD Cowen reiterated a “hold” rating on shares of Orthofix Medical in a research report on Thursday, May 21st. Wall Street Zen downgraded shares of Orthofix Medical from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Barrington Research boosted their price target on shares of Orthofix Medical from $15.00 to $17.00 and gave the stock an “outperform” rating in a research report on Monday, July 6th. Finally, Stifel Nicolaus dropped their price objective on shares of Orthofix Medical from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, May 22nd. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $14.75.

Orthofix Medical Stock Performance

Orthofix Medical stock opened at $10.22 on Wednesday. The firm has a 50 day simple moving average of $10.58 and a 200-day simple moving average of $11.54. Orthofix Medical Inc. has a 1-year low of $8.85 and a 1-year high of $16.99. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.84 and a quick ratio of 1.67. The stock has a market cap of $416.26 million, a price-to-earnings ratio of -6.64 and a beta of 0.68.

Orthofix Medical (NASDAQ:OFIX) last released its quarterly earnings results on Wednesday, August 5th. The medical device company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.02. The firm had revenue of $210.93 million for the quarter, compared to analyst estimates of $209.28 million. Orthofix Medical had a negative net margin of 7.41% and a negative return on equity of 14.05%. On average, analysts expect that Orthofix Medical Inc. will post -1.29 EPS for the current year.

Insider Transactions at Orthofix Medical

In other Orthofix Medical news, insider Aviva Mcpherron sold 3,670 shares of the firm’s stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $9.38, for a total transaction of $34,424.60. Following the completion of the sale, the insider owned 66,330 shares of the company’s stock, valued at $622,175.40. This trade represents a 5.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.70% of the stock is currently owned by company insiders.

About Orthofix Medical

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.